Background: Opisthorchis viverrini (OV)-induced cholangiocarcinoma (CCA) is a significant public health issue in the Great Mekong region, particularly in Thailand. Current treatment options are limited, and early detection remains challenging, hindering effective management of CCA. This study aimed to evaluate the anti-CCA potential of the ethanolic extract of Atractylodes lancea (Thunb.) DC. and assess the applicability of positron emission tomography-computed tomography (PET-CT) as a diagnostic and monitoring tool for CCA in an OV/dimethylnitrosamine (DMN)-induced hamster model.
Aim: This study aimed to evaluate the anticancer activity of Atractylodes lancea (Thunb.) DC. in an
OV/DMN-induced hamster model of cholangiocarcinoma (CCA) and to assess the potential
of PET-CT for early detection and monitoring the progression of CCA.
Methods: Male Syrian hamsters were used to assess the toxicity and
anti-CCA effects of Atractylodes lancea
ethanolic extract. CCA was induced in male Syrian hamsters using a combination
of OV infection and DMN exposure. The ethanolic extract of A. lancea was administered orally for 30 days. PET-CT imaging using
18F-FDG was conducted every 4 weeks after the initiation of CCA.
Results: The ethanolic extract of A. lancea demonstrated promising anti-CCA activity and a favorable
safety profile in the OV/DMN-induced hamster model. PET-CT imaging successfully
detected tumor formation and progression, although modifications to the
radiolabeling approach are needed to enhance specificity for CCA cells. The
median (95% CI) tumor 18F-FDG uptake (percentage of baseline) in CCA-baring and
normal control hamsters at weeks 4, 8, 12, and 16 after OV infection were
comparable (90 vs 100, 130 vs 140, 170 vs 175, and 200 vs 205 at week 4, 8, 12,
and 16 after OV-infection, respectively).
Conclusion: The ethanolic extract of Atractylodes lancea (Thunb.) DC. demonstrates significant potential
as a therapeutic agent against cholangiocarcinoma (CCA), showing both potent
anticancer activity and a safe profile in the hamster model. Additionally,
while PET-CT proves to be a feasible tool for monitoring tumor development and
progression, enhancements in radiolabeling techniques are essential to improve
the specificity for detecting CCA cells and ensure more accurate early
detection and assessment of treatment efficacy. While PET-CT successfully
detected tumor development, further optimization of the radiolabeling technique
is needed to improve its selectivity for CCA cells.
Author
(s) Details
Tullayakorn Plengsuriyakarn
Center of Excellence in Pharmacology and Molecular Biology of Malaria and
Cholangiocarcinoma, Chulabhorn International College of Medicine, Bangkok,
Thailand.
Naoki Matsuda
Division of Radiation Biology and Protection, Radioisotope Center, Institute
of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, Japan.
Juntra Karbwang
Department of Clinical Product Development, Institute of Tropical Medicine
(NEKKEN), Nagasaki University, Nagasaki, Japan.
Vithoon Viyanant
Center of Excellence in Pharmacology and Molecular Biology of Malaria and
Cholangiocarcinoma, Chulabhorn International College of Medicine, Bangkok,
Thailand.
Kenji Hirayama
Department of Immunogenetics, Institute of Tropical Medicine (NEKKEN),
Nagasaki University, Nagasaki, Japan.
Kesara Na-Bangchang
Center of Excellence in Pharmacology and Molecular Biology of Malaria and
Cholangiocarcinoma, Chulabhorn International College of Medicine, Bangkok,
Thailand.
Please see the book here:- https://doi.org/10.9734/bpi/acmms/v6/2905
No comments:
Post a Comment